tiprankstipranks

Tiziana Life Sciences Nears Completion of Promising Long COVID Treatment Study

Story Highlights
  • Tiziana Life Sciences is advancing innovative therapies with intranasal foralumab.
  • The preclinical study of foralumab for long COVID shows promising results in reducing brain inflammation.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Tiziana Life Sciences Nears Completion of Promising Long COVID Treatment Study

Tiziana Life Sciences ( (TLSA) ) has shared an update.

On February 25, 2025, Tiziana Life Sciences announced the nearing completion of a preclinical study for their nasal anti-CD3 treatment, foralumab, which could provide a novel solution for long COVID. This treatment targets microglial activation, a key factor in brain inflammation associated with long COVID, potentially alleviating neurological and psychiatric symptoms. Previous studies have shown foralumab’s effectiveness in reducing inflammation in COVID-19 patients and its potential in treating neuroinflammatory diseases like multiple sclerosis. The announcement highlights Tiziana’s continued efforts to address complex medical challenges with innovative therapies.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody, which has shown promising safety and efficacy in clinical studies. The company aims to improve immunotherapy delivery methods, offering potential advantages over traditional intravenous approaches.

YTD Price Performance: 33.09%

Average Trading Volume: 656,770

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $100.2M

For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App